Greenwich LifeSciences, Inc. (GLSI)
Greenwich LifeSciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Stafford, TX, US. The stock last traded at $15.55, up 0.32% on the session, giving a market capitalisation of $228.2M. On trailing twelve-month figures it carries a trailing P/E of -10.10, a net margin of 0.0%. Its beta of 1.45 implies it has historically moved more than the broad market.
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Greenwich LifeSciences, Inc. is most often compared with the following Healthcare names: